Peripheral T/natural killer-cell lymphoma involving the female genital tract: A clinicopathologic study of 5 cases

• Published in: International journal of hematology 2001-01, Vol.73 (1), p.108-114
• Main Authors: NAKAMURA, Shigeo, KATO, Miyuki, MURAKAMI, Sakae, YAMAO, Kumi, TSUZUKI, Toyonori, ADACHI, Koichi, MIWA, Atsuo, YOSHIDA, Takashi, ICHIMURA, Koichi, YATABE, Yasushi, KAGAMI, Yoshitoyo, SUZUKI, Ritsuro, TAJI, Hirohumi, KONDO, Eisei, ASAKURA, Shoji, KOJIMA, Masaru
• Format: Article
• Language: English
• Subjects: Adult; Biological and medical sciences; Female; Female genital diseases; Genital Neoplasms, Female - diagnosis; Genital Neoplasms, Female - pathology; Gynecology. Andrology. Obstetrics; Hematologic and hematopoietic diseases; Humans; Immunophenotyping; Killer Cells, Natural - pathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, T-Cell - diagnosis; Lymphoma, T-Cell - pathology; Medical sciences; Middle Aged; Treatment Outcome; Tumors
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/BF02981911

Malignant lymphoma of the female genital tract (FGT) is rare. In this study, 5 peripheral T/natural killer (NK)-cell lymphomas (PTCLs) involving the FGT are reported. They include 2 from the uterus and 1 each from ovary, uterus and ovary, and vagina, and were detected between 1996 and 2000. One of the 2 ovarian tumors was bilateral. In all cases, the FGT was the initial site of clinical presentation of disease. Age at presentation ranged from 21 to 52 years (median, 36 years). One case was stage I disease, 2 were stage II, and 2 were stage IV. All 5 tumors were positive for CD3epsilon, and 3 harbored the Epstein-Barr virus, although the detailed immunophenotypic profiles varied. Three were diagnosed as nasal type T/NK-cell lymphoma, 1 as anaplastic large-cell lymphoma (anaplastic lymphoma kinase [ALK]-positive), and 1 as unspecified PTCL of cytotoxic phenotype, according to the forthcoming World Health Organization classification. Four of 5 patients received laparotomy and chemotherapy. Four patients (in stages II and IV) died of disease within 16 months of the initial diagnosis, whereas only 1 patient (in stage I) is alive without disease at 39 months of follow-up. Our experience in this series provided clinically relevant information on diagnosis, treatment, and outcome for extremely rare tumors of the FGT.